An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma.
CONCLUSION: TKM-080301 was generally well tolerated. In this early-phase study, antitumor effect for TKM 080301 was limited. Further evaluation as a single agent in large randomized trials is not warranted.
PMID: 30598500 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: El Dika I, Lim HY, Yong WP, Lin CC, Yoon JH, Modiano M, Freilich B, Choi HJ, Chao TY, Kelley RK, Brown J, Knox J, Ryoo BY, Yau T, Abou-Alfa GK Tags: Oncologist Source Type: research
More News: Cancer & Oncology | Carcinoma | Child Development | Children | Hepatocellular Carcinoma | History of Medicine | Lessons | Liver Cancer | PET Scan | Study | Thrombocytopenia | Toxicology